Showing results (71-80 of 227) with videos related to
Sort By:
Pageof 23
Nuclear Medicine Communications|September 8, 2012
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testesNaoya Hattori, Ajay K Gopal, Andrew T Shields, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2005
Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and olderHerschel Wallen, Theodore A Gooley, H Joachim Deeg, et al.Journal of Clinical Pathology|August 25, 2025
Digital pathology and image analysis of p53 biomarker in lymphomas using two algorithms: correlation with genotype and visual inspectionAnisha Naik, Aarti Kanzaria, Xueyan Chen, et al.Leukemia & Lymphoma|July 3, 2015
Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remissionMazyar Shadman, Ajay K Gopal, Britt Kammerer, et al.Nuclear Medicine Communications|July 31, 2014
90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistributionManuela Matesan, Joseph Rajendran, Oliver W Press, et al.JAMA|February 1, 2022
Diagnosis and Management of Multiple Myeloma: A ReviewAndrew J Cowan, Damian J Green, Mary Kwok, et al.Leukemia & Lymphoma|May 10, 2007
Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell linesShao Xu Ying, Sudeshna Seal, Nissa Abbassi, et al.JCO Oncology Practice|May 6, 2020
Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution StudyRyan C Lynch, Vandana Sundaram, Manisha Desai, et al.Blood|March 13, 2023
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphomaRyan C Lynch, Chaitra S Ujjani, Christina Poh, et al.Blood|April 22, 2011
⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphomaAjay K Gopal, Katherine A Guthrie, Joseph Rajendran, et al.Pageof 23